Author Correction: The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis

Correction to: Scientific Reports10.1038/srep24589, published online 14 April 2016

This Article contains errors.

As a result of an error during figure preparation and assembly:

• data shown in the last panel of Figure 1d (TAK165 200nM) was also used for the last Herceptin panel of Figure 3b (TAK165+ATRA);

• data shown in the second panel of Figure 1d (TAK165 25nM) was also used for the second Herceptin panel of Figure 3b (TAK165).

The corrected Figure 3 is shown below.

Fig. 3.

Effect of TAK165 and ATRA on the HER2 pathway. (a) Western blot analysis of HER2 in the HL60, NB4 and 5 primary cells from AML patients. (b,c) HL60 and NB4 cell flow cytometric cycle proportion assay. The cells were treated with TAK165 (100 nM for HL60, 50 nM for NB4) and ATRA (1 μM for HL60, 2 nM for NB4) in the presence of vehicle or Herceptin (400 μg/ml) for 3 days. (d) CD11b expression in the HL60 and NB4 cells. The cells were treated with TAK165 (100 nM for HL60, 50 nM for NB4) and ATRA (1 μM for HL60, 2 nM for NB4) in the presence of vehicle or Herceptin (400 μg/ml) for 3 days. The data represent the mean ± SD of 3 independent experiments. n.s, p > 0.05.